Search research articles
Contact Us
Filters
Showing results (1-10 of 12) with videos related to
Page
of 2
Sort By:
The Journal of Organic Chemistry
|
April 19, 1996
Putative Diels-Alder-Catalyzed Cyclization during the Biosynthesis of Lovastatin
David J. Witter, John C. Vederas
The Journal of Organic Chemistry
|
June 22, 2010
A divergent approach to the synthesis of 3-substituted-2-pyrazolines: Suzuki cross-coupling of 3-sulfonyloxy-2-pyrazolines
Jonathan B Grimm, Kevin J Wilson, David J Witter
The Journal of Organic Chemistry
|
September 21, 2007
A new strategy for the synthesis of benzylic sulfonamides: palladium-catalyzed arylation and sulfonamide metathesis
Jonathan B Grimm, Matthew H Katcher, David J Witter, et al.
Bioorganic & Medicinal Chemistry Letters
|
May 18, 2007
Aminosuberoyl hydroxamic acids (ASHAs): a potent new class of HDAC inhibitors
Sandro Belvedere, David J Witter, Jiaming Yan, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 20, 2007
Benzo[b]thiophene-based histone deacetylase inhibitors
David J Witter, Sandro Belvedere, Liqiang Chen, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 7, 2007
Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2)
David J Witter, Paul Harrington, Kevin J Wilson, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 9, 2007
Design of novel histone deacetylase inhibitors
Phieng Siliphaivanh, Paul Harrington, David J Witter, et al.
Bioorganic & Medicinal Chemistry Letters
|
February 29, 2008
Phenylglycine and phenylalanine derivatives as potent and selective HDAC1 inhibitors (SHI-1)
Kevin J Wilson, David J Witter, Jonathan B Grimm, et al.
Bioorganic & Medicinal Chemistry Letters
|
March 10, 2009
Exploring the pharmacokinetic properties of phosphorus-containing selective HDAC 1 and 2 inhibitors (SHI-1:2)
Richard W Heidebrecht, Melissa Chenard, Joshua Close, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
February 15, 2017
Evaluation of JAK3 Biology in Autoimmune Disease Using a Highly Selective, Irreversible JAK3 Inhibitor
Fiona Elwood, David J Witter, Jennifer Piesvaux, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 12) with videos related to
Sort By:
Page
of 2
The Journal of Organic Chemistry
|
April 19, 1996
Putative Diels-Alder-Catalyzed Cyclization during the Biosynthesis of Lovastatin
David J. Witter, John C. Vederas
The Journal of Organic Chemistry
|
June 22, 2010
A divergent approach to the synthesis of 3-substituted-2-pyrazolines: Suzuki cross-coupling of 3-sulfonyloxy-2-pyrazolines
Jonathan B Grimm, Kevin J Wilson, David J Witter
The Journal of Organic Chemistry
|
September 21, 2007
A new strategy for the synthesis of benzylic sulfonamides: palladium-catalyzed arylation and sulfonamide metathesis
Jonathan B Grimm, Matthew H Katcher, David J Witter, et al.
Bioorganic & Medicinal Chemistry Letters
|
May 18, 2007
Aminosuberoyl hydroxamic acids (ASHAs): a potent new class of HDAC inhibitors
Sandro Belvedere, David J Witter, Jiaming Yan, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 20, 2007
Benzo[b]thiophene-based histone deacetylase inhibitors
David J Witter, Sandro Belvedere, Liqiang Chen, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 7, 2007
Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2)
David J Witter, Paul Harrington, Kevin J Wilson, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 9, 2007
Design of novel histone deacetylase inhibitors
Phieng Siliphaivanh, Paul Harrington, David J Witter, et al.
Bioorganic & Medicinal Chemistry Letters
|
February 29, 2008
Phenylglycine and phenylalanine derivatives as potent and selective HDAC1 inhibitors (SHI-1)
Kevin J Wilson, David J Witter, Jonathan B Grimm, et al.
Bioorganic & Medicinal Chemistry Letters
|
March 10, 2009
Exploring the pharmacokinetic properties of phosphorus-containing selective HDAC 1 and 2 inhibitors (SHI-1:2)
Richard W Heidebrecht, Melissa Chenard, Joshua Close, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
February 15, 2017
Evaluation of JAK3 Biology in Autoimmune Disease Using a Highly Selective, Irreversible JAK3 Inhibitor
Fiona Elwood, David J Witter, Jennifer Piesvaux, et al.
Page
of 2